The health insurance companies involved are pursuing the goal of concluding discount agreements for the active ingredient raltegravir in accordance with Section 130a (8) SGB V with all suitable pharmaceutical companies. The contract is concluded as part of the open-house originals procedure of the health insurance companies:

Individual negotiations about the content of the contract are not conducted, uniform conditions apply. The health insurance companies do not guarantee individual contractual partners any exclusivity. The contract term is a maximum of 34 months starting on October 1, 2020 (starting with the HEK on July 1, 2021). The contract ends no later than July 31, 2023, regardless of the date of the conclusion of the contract. All further information can be found in the participation and contract documents. If the patent expires before July 31, 2023, the contract ends automatically at the end of the month in which the patent expires.

Joining this open house originals procedure is possible at any time within the contract period. Due to the existence of industrial property rights with regard to the contractual active ingredient, the participation and contract documents are only made available to pharmaceutical companies who offer / market medicinal products for the procedural active ingredient or who make it credible to TK that medicinal products for the procedural active ingredient within the Wanting to offer / sell the contract term.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure designation "Open Procedure" used in the context of this announcement text in accordance with Section IV.1.1) and the specification of the award criteria in accordance with Section II.2.5) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to procurement regulations, the validity of which is not mandatory by law or award regulations.